Key result
Study evaluates SGLT2 inhibitor impact on heart rate variability and turbulence over 24 weeks.
Why the study?
Despite proven cardiovascular benefits of SGLT2i in diabetes mellitus and heart failure, the exact cardioprotective mechanisms remain unconfirmed. This pilot study integrates three areas of interest to explore the electrophysiological, systemic, and metabolic impact of SGLT2i therapy.
Does SGLT2 inhibitor therapy improve cardiac autonomic function (heart rate variability and heart rate turbulence), arrhythmia burden, and cardiometabolic biomarkers over 24 weeks in patients with diabetes mellitus and/or heart failure?
Observational (n=100)
No
Does SGLT2 inhibitor therapy improve cardiac autonomic function (heart rate variability and heart rate turbulence), arrhythmia burden, and cardiometabolic biomarkers over 24 weeks in patients with diabetes mellitus and/or heart failure?
Answers are grounded in this paper and cite their sources.
This proof-of-concept study protocol outlines a 24-week evaluation to explore the underlying electrophysiological, autonomic, and metabolic mechanisms of SGLT2 inhibitors in patients with heart failure and/or diabetes.
Introduction: In the past decade, sodium-glucose co-transporter 2 inhibitors (SGLT2i) have revolutionized therapy in diabetes mellitus (DM) and heart failure (HF) with several trials demonstrating favorable cardiovascular outcomes. Despite the large body of evidence behind the clinical benefit, the exact mechanism through which these medications exert their cardioprotective effects remains unconfirmed. There are several credible hypotheses derived from isolated preclinical and clinical studies. Our observational pilot study aims to integrate three key areas of interest and explore the electrophysiological, systemic, and metabolic impact of SGLT2i therapy. Methods and analysis: This is a single-center proof-of-concept feasibility study with an initial recruitment target of 100 patients with DM, HF, or both, who have a clinical indication for the initiation of an SGLT2i. Eligible participants will be pre-screened and recruited following informed consent to undergo blood tests, cardiac monitoring with a 24 h Holter and body composition analysis prior to the first dose of SGLT2i. Participants will be followed up after 24 weeks for a repeat interventions to assess for any changes post-SGLT2i therapy. The primary outcome of the study will be the cardiac autonomic functional parameters, heart rate variability (HRV) and heart rate turbulence (HRT). The secondary outcomes will cover incidence of atrial arrhythmias and ectopic burden, levels of circulating cardiac and vascular biomarkers including, but not limited to interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α), vascular endothelial growth factor-A (VEGF-A) and fibroblast growth factor-21 (FGF21), a comprehensive array of microRNAs; and body composition for fat mass, fat percentage, and fat-free mass. As a single-center, uncontrolled, pre-post design, while the study cannot conclusively establish causality, findings will be indicative of, and reported as hypothesis-generating associations. Ethics and dissemination: The study is conducted according to the guidelines of the UK Policy Framework for Health and Social Care (2017) and the World Medical Association Declaration of Helsinki (2000), and approved by the Health Research Authority (HRA) and Health and Care Research Wales (HCRW) following clearance from the Research Ethics Committee of East of England- Cambridge South (24/EE0121).
No takes yet. Share an insight, caveat, or question.
Ashok et al. (2026) conducted an observational in Diabetes mellitus, heart failure, or both (n=100). Sodium-glucose co-transporter 2 inhibitors (SGLT2i) vs. Pre-SGLT2i therapy baseline (uncontrolled pre-post design) was evaluated on Cardiac autonomic functional parameters, heart rate variability (HRV) and heart rate turbulence (HRT). SGLT2 inhibitor therapy is being evaluated in a 100-patient, 24-week observational study for its impact on heart rate variability and turbulence; no results are reported in this protocol.
Synapse has enriched 10 related papers. Consider them for comparative context: